NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01909453,Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma,https://clinicaltrials.gov/study/NCT01909453,COLUMBUS,COMPLETED,"This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. A total of approximately 900 patients will be randomized.

Part 1:

Patients will be randomized in a 1:1:1 ratio to one of 3 treatment arms:

1. LGX818 450 mg QD plus MEK162 45 mg BID (denoted as Combo 450 arm)
2. LGX818 300 mg QD monotherapy (denoted as LGX818 arm) or
3. vemurafenib 960 mg BID (denoted as vemurafenib arm)

Part 2:

Patients will be randomized in a 3:1 ratio to one of the 2 treatment arms:

1. LGX818 300 mg QD plus MEK162 45 mg BID (denoted as Combo 300 arm) or
2. LGX818 300 mg QD monotherapy (denoted as LGX818 arm)",YES,Melanoma,DRUG: LGX818|DRUG: MEK162|DRUG: vemurafenib,"Part 1: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) in Combo 450 Group as Compared to Vemurafenib Group, PFS was defined as the time from the date of randomization to the date of the first documented disease progression (PD) or death due to any cause, whichever occurs first. PFS was determined based on tumor assessment (RECIST version 1.1 criteria) as per BIRC/central review and survival information. If a participant did not had an event at the time of the analysis cut-off or at the start of any new anti-cancer therapy, data was censored at the date of last adequate tumor assessment. PD was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 square millimeter (mm\^2)., From randomization until documented disease progression (PD), initiation of new anti-cancer therapy, censoring date or death, whichever occurred first (up to 29 months)|Part 1: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) in Combo 450 Group as Compared to LGX818 Group, PFS was defined as the time from the date of randomization to the date of the first documented disease progression (PD) or death due to any cause, whichever occurs first. PFS was determined based on tumor assessment (RECIST version 1.1 criteria) as per BIRC and survival information. If a participant did not had an event at the time of the analysis cut-off or at the start of any new anti-cancer therapy, data was censored at the date of last adequate tumor assessment. PD was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 mm\^2., From randomization until documented disease progression (PD), initiation of new anti-cancer therapy, censoring date or death, whichever occurred first (up to 29 months), excluding Part 1: LGX818 300 mg group; up to 35 months for Part 1: LGX 300 mg group","Part 2: Progression Free Survival (PFS) by BIRC in Combo 300 Group as Compared to LGX818 Group, PFS was defined as the time from the date of randomization to the date of the first documented disease progression (PD) or death due to any cause, whichever occurs first. PFS was determined based on tumor assessment (RECIST version 1.1 criteria) as per BIRC and survival information. If a participant did not had an event at the time of the analysis cut-off or at the start of any new anti-cancer therapy, data was censored at the date of last adequate tumor assessment. PD was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 mm\^2., From randomization until documented disease progression (PD), initiation of new anti-cancer therapy, censoring date or death, whichever occurred first (up to 35 months)|Part 1: Overall Survival (OS), Overall survival was defined as the time from the date of randomization to the date of death due to any cause. If a death had not been observed by the date of analysis cutoff, OS was censored at the date of last contact., From randomization until documented disease progression (PD), initiation of new anti-cancer therapy, censoring date or death, whichever occurred first (up to 38 months)|Part 1: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) as Graded by National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03, AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that results in death; is life-threatening; requires inpatient hospitalization/prolongation of existing hospitalization; results in persistent/significant disability/incapacity; results in congenital anomaly/birth defect or that is considered to be important medical event. As per NCI-CTCAE version 4.03, severity was graded as Grade 1: asymptomatic/mild symptoms, clinical/diagnostic observations only; Grade 2: moderate, minimal, local/noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe/medically significant but not immediately life-threatening, hospitalization/prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence; Grade 5: death. AEs of all grades were reported., Baseline up to 30 days from last dose of study drug (up to 30 months), excluding Part 1: LGX818 300 mg group; up to 36 months for Part 1 LGX 300 mg group|Part 1: Number of Participants With Clinically Notable Shift From Baseline in Laboratory Parameter Values Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Grade, Version 4.03, Number of participants with clinically notable shift from baseline in laboratory parameter values based on national cancer institute common terminology criteria (NCI-CTCAE) grade, Version 4.03 were graded from Grades 1 to 5. Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death. Clinically notable shift from baseline in laboratory parameter = worsening by at least 2 grades or to \>=grade 3., Baseline up to 30 days from last dose of study drug (up to 30 months), excluding Part 1: LGX818 300 mg group; up to 36 months for Part 1 LGX 300 mg group|Part 1: Number of Participants With Newly Occurring Notably Abnormal Vital Signs, Notably abnormal vital signs were: Low/high systolic blood pressure (SBP) (millimeter of mercury \[mmHg\]): less than or equal to (\<=) 90 mmHg with decrease from baseline of greater than or equal to (\>=) 20 mmHg/\>= 160 mmHg with increase from baseline of \>=20 mmHg. Low/high diastolic blood pressure (DBP) \[mmHg\]: \<= 50 mmHg with decrease from baseline of \>=15 mmHg/\>=100 mmHg with increase from baseline of \>=15 mmHg. Low/high Pulse rate: \<=50 beats per minute (bpm) with decrease from baseline of \>=15 bpm/\>= 120 bpm with increase from baseline of \>=15 bpm. Low/high Weight \[kilogram\]: \>=20 percent (%) decrease from baseline/\>= 10% increase from baseline. Low/high Body temperature degree Celsius (C): \<= 36 degree C/\>= 37.5 degree C., Baseline up to 30 days from last dose of study drug (up to 30 months), excluding Part 1: LGX818 300 mg group; up to 36 months for Part 1 LGX 300 mg group|Part 1: Number of Participants With Newly Occurring Notable Electrocardiogram (ECG) Values, Newly occurring notable ECG values were reported for QT (millisecond \[ms\]), QTcF (millisecond), QTcB (millisecond) and heart rate (beats per minute). Newly occurring was defined as participants not meeting criterion at baseline and meeting criterion post-baseline. Ranges for newly occurring notable ECG values (QT, QTcF, QTcB) are New greater than (\>) 450, New \>480, New \>500, Increase from baseline \>30, Increase from baseline \>60. Heart rate: New \<60, New \>100 was considered as newly occurring notable value., Baseline up to 30 days from last dose of study drug (up to 30 months), excluding Part 1: LGX818 300 mg group; up to 36 months for Part 1 LGX 300 mg group|Part 1: Number of Participants With Worst Post-baseline Left Ventricular Dysfunction Events (LVEF) Values by Multigated Acquisition (MUGA) Scans or Transthoracic Echocardiograms (ECHO), by CTCAE Grade, Participants with worst post-baseline LVEF Values were graded as Grade 0: Non missing value below Grade 2; Grade 2: LVEF between 40% and 50% or absolute reduction from baseline \>=10% and \< 20%; Grade 3: LVEF between 20% and 39% or absolute reduction from baseline \>=20%; Grade 4: LVEF lower than 20%. Baseline was defined as the last non-missing value prior to the first dose of study treatment. Missing data were due to participants who died or withdrew consent prior to the first scheduled evaluation or missed evaluations as protocol deviations., Baseline up to 30 days from last dose of study drug (up to 30 months), excluding Part 1: LGX818 300 mg group; up to 36 months for Part 1 LGX 300 mg group|Part 1: Number of Participants With Dermatologic-related Adverse Events of Special Interest (AESI) Graded According to the National Cancer Institute Common Terminology Criteria (NCI-CTCAE) v4.03, AESI consisted of events for which there was a specific clinical interest with regard to LGX818 and/or MEK162 treatment. Dermatologic-related AESI included rash, photosensitivity, nail disorders, skin infections, severe cutaneous adverse reactions and Palmar-plantar erythrodysaesthesia (PPE) syndrome. As per NCI-CTCAE version 4.03, severity was graded as Grade 1: asymptomatic/mild symptoms, clinical/diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local/noninvasive intervention indicated, limiting age-appropriate instrumental ADL; Grade 3: severe/medically significant but not immediately life-threatening, hospitalization/prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. AEs of grade 3 or 4 are reported in this outcome measure., Baseline up to 30 days from last dose of study drug (up to 30 months), excluding Part 1: LGX818 300 mg group; up to 36 months for Part 1 LGX 300 mg group|Part 1: Number of Participants With Ocular-related Adverse Events of Special Interest (AESI) Graded According to the National Cancer Institute Common Terminology Criteria (NCI-CTCAE) v4.03, AESI consisted of events for which there was a specific clinical interest with regard to LGX818 and/or MEK162 treatment. Ocular-related AESI included retinopathy excluding retinal vein occlusion (RVO), RVO and uveitis-type events. As per NCI-CTCAE version 4.03, severity was graded as Grade 1: asymptomatic/mild symptoms, clinical/diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local/noninvasive intervention indicated, limiting age-appropriate instrumental ADL; Grade 3: severe/medically significant but not immediately life-threatening, hospitalization/prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. AEs of grade 3 or 4 are reported in this outcome measure., Baseline up to 30 days from last dose of study drug (up to 30 months), excluding Part 1: LGX818 300 mg group; up to 36 months for Part 1 LGX 300 mg group|Part 2: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) as Graded by National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03, AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that results in death; is life-threatening; requires inpatient hospitalization/prolongation of existing hospitalization; results in persistent/significant disability/incapacity; results in congenital anomaly/birth defect or that is considered to be important medical event. As per NCI-CTCAE version 4.03, severity was graded as Grade 1: asymptomatic/mild symptoms, clinical/diagnostic observations only; Grade 2: moderate, minimal, local/noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe/medically significant but not immediately life-threatening, hospitalization/prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence; Grade 5: death. AEs of all grades were reported., Baseline up to 30 days after last dose of study drug (up to 36 months)|Part 2: Number of Participants With Clinically Notable Shift From Baseline in Laboratory Parameter Values Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Grade, Version 4.0, Number of participants with clinically notable shift from baseline in laboratory parameter values based on national cancer institute common terminology criteria (NCI-CTCAE) grade, Version 4.0 were graded from Grades 1 to 5. Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death. Clinically notable shift from baseline in laboratory parameter = worsening by at least 2 grades or to \>=grade 3., Baseline up to 30 days after last dose of study drug (up to 36 months)|Part 2: Number of Participants With Newly Occurring Notably Abnormal Vital Signs, Notably abnormal vital signs were: Low/high systolic blood pressure (SBP) in millimeter of mercury (mmHg): less than or equal to (\<=) 90 mmHg with decrease from baseline of greater than or equal to (\>=) 20 mmHg/\>= 160 mmHg with increase from baseline of \>=20 mmHg, Low/high diastolic blood pressure (DBP) \[mmHg\]: \<=50 mmHg with decrease from baseline of \>=15 mmHg/\>=100 mmHg with increase from baseline of \>=15 mmHg, Low/high pulse rate \[bpm\]: \<=50 bpm with decrease from baseline of \>=15 bpm/\>=120 bpm with increase from baseline of \>=15 bpm, Low/high weight (kg): \>=20 % decrease from baseline/\>= 10% increase from baseline Low/high Body temperature degree C): \<= 36°C/\>= 37.5 degree C., Baseline up to 30 days after last dose of study drug (up to 36 months)|Part 2: Number of Participants With Newly Occurring Notable ECG Values, Newly occurring notable ECG values were reported for QT (ms), QTcF (ms), QTcB (ms) and heart rate (bpm). Newly occurring was defined as participants not meeting criterion at baseline and meeting criterion post-baseline. Ranges for newly occurring notable ECG values (QT, QTcF, QTcB) are New \>450, New \>480, New \>500, increase from baseline \>30, Increase from baseline \>60. Heart rate: New \< 60, New \>100 was considered as newly occurring notable value., Baseline up to 30 days after last dose of study drug (up to 36 months)|Part 2: Number of Participants With Worst Post-baseline Left Ventricular Dysfunction Events (LVEF) Values by Multigated Acquisition (MUGA) Scans or Transthoracic Echocardiograms (ECHO), by CTCAE Grade, Participants with worst post-baseline LVEF Values were graded as Grade 0: Non missing value below Grade 2; Grade 2: LVEF between 40% and 50% or absolute reduction from baseline \>=10% and \< 20%;Grade 3: LVEF between 20% and 39% or absolute reduction from baseline \>=20%; Grade 4: LVEF lower than 20%. Baseline was defined as the last non-missing value prior to the first dose of study treatment. Missing data were due to participants who died or withdrew consent prior to the first scheduled evaluation or missed evaluations as protocol deviations., Baseline up to 30 days after last dose of study drug (up to 36 months)|Part 2: Number of Participants With Dermatologic-related Adverse Events of Special Interest (AESI) Graded According to the National Cancer Institute Common Terminology Criteria (NCI-CTCAE) v4.03, AESI consisted of events for which there was a specific clinical interest with regard to LGX818 and/or MEK162 treatment. Dermatologic-related AESI included rash, photosensitivity, nail disorders, skin infections, severe cutaneous adverse reactions and PPE syndrome. As per NCI-CTCAE version 4.03, severity was graded as Grade 1: asymptomatic/mild symptoms, clinical/diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local/noninvasive intervention indicated, limiting age-appropriate instrumental ADL; Grade 3: severe/medically significant but not immediately life-threatening, hospitalization/prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. AEs of grade 3 or 4 are reported are reported in this outcome measure., Baseline up to 30 days after last dose of study drug (up to 36 months)|Part 2: Number of Participants With Ocular-related Adverse Events of Special Interest (AESI) Graded According to the National Cancer Institute Common Terminology Criteria (NCI-CTCAE) v4.03, AESI consisted of events for which there was a specific clinical interest with regard to LGX818 and/or MEK162 treatment. Ocular-related AESI included retinopathy excluding RVO, RVO and uveitis-type events. As per NCI-CTCAE version 4.03, severity was graded as Grade 1: asymptomatic/mild symptoms, clinical/diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local/noninvasive intervention indicated, limiting age-appropriate instrumental ADL; Grade 3: severe/medically significant but not immediately life-threatening, hospitalization/prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. AEs of grade 3 or 4 are reported in this outcome measure., Baseline up to 30 days after last dose of study drug (up to 36 months)|Part 2: Overall Survival (OS), From randomization until documented disease progression (PD), initiation of new anti-cancer therapy, censoring date or death, whichever occurred first (up to 38 months)|Part 1 and Part 2: Objective Response Rate (ORR), ORR, calculated as the percentage of participants with a best overall response of complete response (CR) or partial response (PR). CR was defined as disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Results are reported for confirmed BIRC response., From randomization until disease progression, censoring date or death, whichever occurred first (up to 29 months for Part 1, excluding Part 1: LGX818 300 mg group; up to 35 months for Part 2 and Part 1 LGX 300 mg group)|Part 1 and Part 2: Time to Objective Response (TTR), TTR was the time between date of randomization until first documented response of CR or PR. Participants who did not achieve a PR or CR were censored at the last adequate tumor assessment date when they did not have a PFS event or at maximum follow-up (i.e. first patient first visit \[FPFV\] to last patient last visit \[LPLV\] used for the analysis) when they had a PFS event. CR was defined as disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. TTR was estimated in the treatment arms using a Kaplan-Meier method. TTR was based on central review., From randomization until disease progression, censoring date or death, whichever occurred first (up to 29 months for Part 1, excluding Part 1: LGX818 300 mg group; up to 35 months for Part 2 and Part 1 LGX 300 mg group)|Part 1 and Part 2: Disease Control Rate (DCR), DCR was calculated as the percentage of participants with a best overall response (BOR) of CR, PR, or stable disease (SD). CR was defined as disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Two sets of DCR were considered, one for confirmed and one for unconfirmed responses. Results are reported for confirmed and unconfirmed responses combined. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. DCR was based on central review., From randomization until disease progression or death, whichever occurred first (up to 29 months for Part 1, excluding Part 1: LGX818 300 mg group; up to 35 months for Part 2 and Part 1 LGX 300 mg group)|Part 1 and Part 2: Duration of Response (DOR), DOR was calculated, as the time from the date of first documented response (CR or PR) to the first documented progression or death due to underlying cancer. DOR was estimated for responders (i.e. participants achieving at least once CR or PR) only using a Kaplan-Meier method. CR was defined as disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. If a participant with a CR or PR had no progression or death due to underlying disease, the participant was censored at the date of last adequate tumor assessment. Results are based on confirmed BIRC response., From randomization until disease progression, censoring date or death, whichever occurred first (up to 29 months for Part 1, excluding Part 1: LGX818 300 mg group; up to 35 months for Part 2 and Part 1 LGX 300 mg group)|Part 1 and Part 2: Time to Definitive 10% Deterioration in the Function Assessment Cancer Therapy-melanoma (FACT-M) Subscale, FACT-M:melanoma specific questionnaire to assess participant health-related quality of life. Melanoma specific subscale consists of 16 items related to signs,symptoms,physical/social activities most relevant to participants with advanced-stage melanoma. Other items include physical, functional and social/family well-being (7 items each),emotional well-being (6 items),surgery specific concerns related to melanoma(8 items,not included in this study). Each item range from 0(not at all) to 4(very much), combined to produce subscale scores.Total score range for FACT-M excluding surgery specific items is 0 to 172,higher scores represent better quality of life.Melanoma subscale score range from 0(worst response) to 64(best response),higher score indicated better quality of life. Time to definitive 10% deterioration:time from date of randomization to date of event with at least 10% relative to baseline worsening of corresponding scale score with no later improvement or death due to any cause., Date of randomization to date of event or death due to any cause, which ever occurred first (up to 29 months for Part 1, excluding Part 1: LGX818 300 mg group; up to 35 months for Part 2 and Part 1 LGX 300 mg group)|Part 1 and Part 2: Time to Definitive 10% Deterioration in the Global Health Status Score of the European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC QLQ-C30), EORTC QLQ-C30 is 30 item questionnaire composed of 5 multi-item functional subscales (physical, role, cognitive, emotional, social functioning), 3 multi-item symptom scales (fatigue, nausea/vomiting, and pain), global health/quality of life (QOL) subscale and 6 single items assessing other cancer related symptoms (dyspnea, sleep disturbance, appetite, diarrhea, constipation and financial impact of cancer). It employed twenty-eight 4 point Likert scales with responses from ""not at all"" to ""very much"" and two 7 point Likert scales for global health and overall QOL. Global health status scale score ranged from 0 to 100. Higher score represented better level of functioning. Time to definitive 10% deterioration: time from date of randomization to date of event with at least 10% relative to baseline worsening of corresponding scale score with no later improvement or death due to any cause., Date of randomization to date of event or death due to any cause, which ever occurred first (maximum up to 29 months for Part 1, excluding Part 1: LGX818 300 mg group; up to 35 months for Part 2 and Part 1 LGX 300 mg group)|Part 1 and Part 2: Change From Baseline in the Function Assessment Cancer Therapy-melanoma (FACT-M) Subscale at Day 1 of Cycle 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and End of Treatment Visit, FACT-M: melanoma specific questionnaire to assess participant health-related quality of life. Melanoma specific subscale consists of 16 items related to signs, symptoms, physical/social activities most relevant to participants with advanced-stage melanoma. Other items include physical, functional and social/family well-being (7 items each),emotional well-being (6 items),surgery specific concerns related to melanoma(8 items, not included in this study). Each item range from 0(not at all) to 4(very much), combined to produce subscale scores. Total score range for FACT-M excluding surgery specific items is 0 to 172,higher scores represented better quality of life. Melanoma subscale score range from 0(worst response) to 64(best response),higher score indicated better quality of life., Baseline (Day 1 of Cycle 1), Day 1 of Cycle 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and end of treatment visit (within14 days after the last dose of study drug)|Part 1 and Part 2: Change From Baseline in EuroQoL-5 Dimension-5 Level (EQ-5D-5L) Index Score at Day 1 of Cycle 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and End of Treatment Visit, EQ-5D-5L is a standardized participant completed questionnaire that measures health status in terms of a single index value or utility score. EQ-5D-5L consisted of two components: a health state profile (descriptive system) and a visual analogue scale (VAS) in which participants rate their overall health status from 0 (worst imaginable) to 100 (best imaginable), where higher scores indicated better health status. EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L health status index score range between 0 to 1. Higher score indicated better health status., Baseline (Day 1 of Cycle 1), Day 1 of Cycle 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and end of treatment visit (within14 days after the last dose of study drug)|Part 1 and Part 2: Change From Baseline in Global Health Status Score of EORTC QLQ-C30 at Day 1 of Cycle 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and End of Treatment Visit, EORTC QLQ-C30 contains 30 items and is composed of multi-item and single-item measures. These include 5 functional scales (physical, role, emotional, cognitive and social functioning), 3 symptom scales (fatigue, nausea/vomiting, and pain), 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial impact) and a global health status/quality of life (QOL) scale. The questionnaire employs 28 4-point Likert scales with responses from ""not at all"" to ""very much"" and two 7-point Likert scales for global health and overall QOL. Responses to all items converted to 0 to 100 scale. For functional and global QOL scales, higher scores represent a better level of functioning/QOL. For symptom-oriented scales, a higher score represents more severe symptoms., Baseline (Day 1 of Cycle 1), Day 1 of Cycle 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and end of treatment visit (within14 days after the last dose of study drug)|Part 1 and Part 2: Change From Baseline in Emotional Functioning Scale Score of the EORTC QLQ-C30 at Day 1 of Cycle 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and End of Treatment Visit, EORTC QLQ-C30 contains 30 items and is composed of multi-item and single-item measures. These include 5 functional scales (physical, role, emotional, cognitive and social functioning), 3 symptom scales (fatigue, nausea/vomiting, and pain), 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial impact) and a global health status/quality of life (QOL) scale. The questionnaire employs 28 4-point Likert scales with responses from ""not at all"" to ""very much"" and two 7-point Likert scales for global health and overall QOL. Responses to all items converted to 0 to 100 scale. For functional and global QOL scales, higher scores represent a better level of functioning/QOL. For symptom-oriented scales, a higher score represented more severe symptoms., Baseline (Day 1 of Cycle 1), Day 1 of Cycle 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and end of treatment visit (within14 days after the last dose of study drug)|Part 1 and Part 2: Change From Baseline in Physical Functioning Scale Score of the EORTC QLQ-C30 at Day 1 of Cycle 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and End of Treatment Visit, EORTC QLQ-C30 contains 30 items and is composed of multi-item and single-item measures. These include 5 functional scales (physical, role, emotional, cognitive and social functioning), 3 symptom scales (fatigue, nausea/vomiting, and pain), 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial impact) and a global health status/quality of life (QOL) scale. The questionnaire employs 28 4-point Likert scales with responses from ""not at all"" to ""very much"" and two 7-point Likert scales for global health and overall QOL. Responses to all items converted to 0 to 100 scale. For functional and global QOL scales, higher scores represented a better level of functioning/QOL. For symptom-oriented scales, a higher score represented more severe symptoms., Baseline (Day 1 of Cycle 1), Day 1 of Cycle 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and end of treatment visit (within14 days after the last dose of study drug)|Part 1 and Part 2: Change From Baseline in Social Functioning Scale Score of the EORTC QLQ-C30 at Day 1 of Cycle 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and End of Treatment Visit, EORTC QLQ-C30 contains 30 items and is composed of multi-item and single-item measures. These include 5 functional scales (physical, role, emotional, cognitive and social functioning), 3 symptom scales (fatigue, nausea/vomiting, and pain), 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial impact) and a global health status/quality of life (QOL) scale. The questionnaire employs 28 4-point Likert scales with responses from ""not at all"" to ""very much"" and two 7-point Likert scales for global health and overall QOL. Responses to all items converted to 0 to 100 scale. For functional and global QOL scales, higher scores represented a better level of functioning/QOL. For symptom-oriented scales, a higher score represented more severe symptoms., Baseline (Day 1 of Cycle 1), Day 1 of Cycle 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and end of treatment visit (within14 days after the last dose of study drug)|Part 1 and Part 2: Number of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG PS), ECOG: participant's performance status was measured on a 6-point scale: 0= fully active/able to carry on all pre-disease activities without restriction; 1= restricted in physically strenuous activity but ambulatory and able to carry out work of a light and sedentary nature; 2= ambulatory and capable of all self-care, but unable to carry out any work activities, up and about more than 50% of waking hours; 3= capable of only limited self-care, confined to bed/chair \>50% of waking hours; 4= completely disabled, cannot carry on any self-care, totally confined to bed/chair: 5= dead., Part 1 and Part 2: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 31)|Part 1: Plasma Concentrations of LGX 818, Cycle 1 Day 1: pre-dose, 0.5, 1.5, 4 to 8 hours post dose; Cycle 2 Day 1: pre-dose; Cycle 3 Day 1: pre-dose|Part 2: Plasma Concentrations of LGX 818, Cycle 1 Day 1: pre-dose, 0.5, 1.5, 4 to 8 hours post dose; Cycle 2 Day 1: pre-dose; Cycle 3 Day 1: pre-dose|Part 1: Plasma Concentrations of MEK162, Cycle 1 Day 1: pre-dose, 0.5, 1.5, 4 to 8, hours post dose; Cycle 2 Day 1: pre-dose; Cycle 3 Day 1: pre-dose|Part 2: Plasma Concentrations of MEK162, Cycle 1 Day 1: pre-dose, 0.5, 1.5, 4 to 8, hours post dose; Cycle 2 Day 1: pre-dose; Cycle 3 Day 1: pre-dose|Part 1 and Part 2: Time to Definitive 1 Point Deterioration in Eastern Cooperative Oncology Group Performance Status (ECOG PS), ECOG: participant's performance status was measured on a 6-point scale: 0= fully active/able to carry on all pre-disease activities without restriction; 1= restricted in physically strenuous activity but ambulatory and able to carry out work of a light and sedentary nature; 2= ambulatory and capable of all self-care, but unable to carry out any work activities, up and about more than 50 percent (%) of waking hours; 3= capable of only limited self-care, confined to bed/chair \>50% of waking hours; 4= completely disabled, cannot carry on any self-care, totally confined to bed/chair: 5= dead. Definitive deterioration was defined as death due to any cause or decrease in ECOG PS by at least one category from baseline score with no subsequent improvement., Baseline up to 30 days from last dose of study drug (up to 30 months for Part 1, excluding Part 1: LGX818 300 mg group; up to 36 months for Part 2 and Part 1 LGX 300 mg group)",,Pfizer,,ALL,"ADULT, OLDER_ADULT",PHASE3,922,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CMEK162B2301|C4221004|2013-001176-38,2013-09-12,2016-11-09,2024-09-03,2013-07-26,2021-07-12,2025-03-25,"UAB Comprehensive Cancer Center, Birmingham, Alabama, 35233-1932, United States|UAB The Kirklin Clinic, Birmingham, Alabama, 35233-1932, United States|Retinal Consultants of Alabama P.C., Birmingham, Alabama, 35233, United States|UAB Callahan Eye Hospital, Birmingham, Alabama, 35233, United States|UAB Comprehensive Cancer Center, Birmingham, Alabama, 35243, United States|University of Alabama at Birmingham, Birmingham, Alabama, 35243, United States|University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|Highlands Oncology Group, Fayetteville, Arkansas, 72703, United States|Highlands Oncology Group, Rogers, Arkansas, 72758, United States|Highlands Oncology Group - Fayetteville, Springdale, Arkansas, 72762, United States|UC Irvine Medical Center, Orange, California, 92868-3201, United States|UC Irvine Medical Center, Orange, California, 92868, United States|Rocky Mountain Cancer Centers (Williams) - USOR, Aurora, Colorado, 80012-5405, United States|Rocky Mountain Cancer Centers, Boulder, Colorado, 80303, United States|Rocky Mountain Cancer Centers, Colorado Springs, Colorado, 80907, United States|Rocky Mountain Cancer Centers (Williams) - USOR, Denver, Colorado, 80218, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, 80228, United States|Specialty Eye Care, Parker, Colorado, 80134, United States|Rocky Mountain Cancer Centers, Pueblo, Colorado, 81008, United States|University Cancer Institute, Boynton Beach, Florida, 33426, United States|University of Miami, Miami, Florida, 33136, United States|University of Illinois at Chicago, Chicago, Illinois, 60612-4325, United States|University of Illinois Hospital and Health Sciences System - Investigational Drug Service, Chicago, Illinois, 60612-7234, United States|Eye & Ear Infirmary- Opthalmology, Chicago, Illinois, 60612, United States|University of Illinois at Chicago, Chicago, Illinois, 60612, United States|University of Illinois Hospital and Health Sciences System, Chicago, Illinois, 60612, United States|University of Illinois Medical Center, Chicago, Illinois, 60612, United States|Goshen Center For Cancer Care, Goshen, Indiana, 46526-4810, United States|Lack's Cancer Center at Mercy Health Saint Mary's, Grand Rapids, Michigan, 49503, United States|Mercy Health Hauenstein Neuroscience Center Neuro-Ophthalmology (Clinic), Grand Rapids, Michigan, 49503, United States|Retina Specialists of Michigan, Grand Rapids, Michigan, 49525, United States|Hattiesburg Clinic Oncology Hem, Hattiesburg, Mississippi, 39401, United States|Jackson Oncology Associates - St. Dominic Hospital, Jackson, Mississippi, 39202, United States|Jackson Oncology Associates - St. Dominic Hospital, Jackson, Mississippi, 39216-4608, United States|Jackson Oncology Associates, PLLC, Jackson, Mississippi, 39216, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Hackensack University Medical Center, Hackensack, New Jersey, 7601, United States|Hackensack University Medical Cente, Hackensack, New Jersey, 7601, United States|Investigational Drug Service, Department of Pharmacy (Investigational Product), Rochester, New York, 14642, United States|University of Rochester Medical Center - PPDS, Rochester, New York, 14642, United States|Tulsa Cancer Institute PLLC, Tulsa, Oklahoma, 74146, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15232, United States|University of Tennessee Medical Center Cancer Institute, Knoxville, Tennessee, 37920, United States|Dr. Dennis B. Kay (Ophthalmologist), Dallas, Texas, 75231, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, 75390, United States|University of Vermont Medical Center, Burlington, Vermont, 05401-1473, United States|University of Vermont Medical Center, Burlington, Vermont, 05401, United States|University of Vermont Cancer Center, Burlington, Vermont, 05405, United States|Virginia Cancer Specialists, PC, Alexandria, Virginia, 22304, United States|Virginia Cancer Specialists, Arlington, Virginia, 22205, United States|Virginia Cancer Specialists (Leesburg) - USOR, Fairfax, Virginia, 22031, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, 22031, United States|Virginia Cancer Specialists, Fairfax, Virginia, 22031, United States|Northern Virginia Ophthalmology Associates, Fairfax, Virginia, 22033, United States|Northern Virginia Ophthalmology Associates, Falls Church, Virginia, 22044, United States|Virginia Cancer Specialists, PC, Gainesville, Virginia, 20155, United States|Virginia Cancer Specialists (Leesburg) - USOR, Leesburg, Virginia, 20176, United States|Virginia Cancer Specialists, PC, Leesburg, Virginia, 20176, United States|Wenatchee Valley Hospital & Clinics, Wenatchee, Washington, 98801, United States|Wenatchee Valley Hospitals & Clinics, Wenatchee, Washington, 98801, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, 98801, United States|Fundación CENIT para la Investigación en Neurociencias, Caba, Buenos Aires, C1125ABD, Argentina|Organización Médica de Investigación, Buenos Aires, Ciudad Autónoma DE Buenosaires, C1015ABO, Argentina|Fundación Investigar, Buenos Aires, Ciudad Autónoma DE Buenosaires, C1025ABI, Argentina|Sanatorio de La Providencia, Buenos Aires, Ciudad Autónoma DE Buenosaires, C1050AAK, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Ciudad Autónoma DE Buenosaires, C1181ACH, Argentina|Instituto Médico Especializado Alexander Fleming, Buenos Aires, Ciudad Autónoma DE Buenosaires, C1426ANZ, Argentina|Centro de Diagnóstico Dr. Enrique Rossi, Buenos Aires, Ciudad Autónoma DE Buenosaires, C1428DDO, Argentina|Lake Macquarie Private Hospital, Gateshead, New South Wales, 02290, Australia|HPS Pharmacy, Southport, Queensland, 4215, Australia|Tasman Oncology Research, Southport, Queensland, 4215, Australia|Vision Optical, Southport, Queensland, 4215, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|The Queen Elizabeth Hospital, Woodville, South Australia, 5011, Australia|The Alfred Hospital, Melbourne, Victoria, 3004, Australia|The Alfred Hospital, Prahran, Victoria, 3004, Australia|Sir Charles Gairdner Hospital Pharmacy Department, Nedlands, Western Australia, 6009, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, 6009, Australia|AMO - Assistência Multidisciplinar em Oncologia, Salvador, Bahia, 41825-010, Brazil|Instituto de Medicina Integral Professor Fernando Figueira, Recife, Pernambuco, 50070-550, Brazil|Associação Hospital de Caridade Ijuí, Ijuí, RIO Grande DO SUL, 98700-000, Brazil|Hospital de Clinicas de Porto Alegre (HCPA) - PPDS, Porto Alegre, RIO Grande DO SUL, 90035-003, Brazil|Fundação PIO XII, Barretos, SÃO Paulo, 14784-400, Brazil|Liga Norte Riograndense Contra O Cancer, Natal, 59062-000, Brazil|Hospital do Cancer I - Instituto Nacional de Cancer - INCA, Rio de Janeiro, 20220-410, Brazil|INCA Instituto Nacional de Cancer, Rio de Janeiro, 20220-410, Brazil|Hospital BP Mirante, Sao Paulo, 01321-001, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, T2N 4N2, Canada|SunnyBrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|Sunnybrook Research Institute, Toronto, Ontario, M4N 3M5, Canada|Toronto General Hospital, Toronto, Ontario, M5G 2C4, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada|Centre Hospitalier De L'Universite De Montreal Hospital Notre Dame, Montreal, Quebec, H2L 4M1, Canada|CHUM Notrea Dame Hospital, Montreal, Quebec, H2L 4M1, Canada|Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, H2X 3E4, Canada|McGill University Health center, Montreal, Quebec, H4A 3J1, Canada|CHU de Quebec-Universite Laval, Quebec City, Quebec, G1V 4G2, Canada|CHU de Quebec- L'Hotel-Dieu de Quebec, Québec, Quebec, G1R 2J6, Canada|Centre de Sante Et Services Sociaux Richelieu Yamaska, Sainte Hyacinthe, Quebec, J2S 4Y8, Canada|Centre Hospitalier Universitaire de Quebec - Hotel - Dieu de Quebec - Universite Laval, Quebec, G1R 2J6, Canada|CHU de Quebec-Universite Laval - L' Hotel - Dieu de Quebec, Quebec, G1R 2J6, Canada|Hospital Universitario San Ignacio, Bogotá, Distrito Capital DE Bogotá, 110311, Colombia|Hospital Universitario San Ignacio, Bogotá, Pbx (57-1), 3208320, Colombia|Mou/Mmci - Ppds, Brno, Jihomoravský KRAJ, 656 53, Czechia|Fakultni nemocnice Ostrava, Ostrava, Moravskoslezský KRAJ, 70852, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Praha, Hlavní Mesto, 100 34, Czechia|Vseobecna Fakultni Nemocnice V Praze, Praha 2, Praha, Hlavní Mesto, 128 08, Czechia|Fakultni nemocnice u sv. Anny v Brne, Brno, 656 91, Czechia|Fakultni nemocnice Olomouc, Olomouc, 775 20, Czechia|Fakultni nemocnice Ostrava, Ostrava Poruba, 708 52, Czechia|General Faculty Hospital, Praha 2, 128 08, Czechia|Vseobecna Fakultni Nemocnice V Praze-U Nemocnice 499/2, Praha, 128 08, Czechia|Vseobecna Fakultni Nemocnice V Praze, Praha, 128 08, Czechia|CHU de Nice, Nice, Alpes-maritimes, 06202, France|Hôpital Saint-André, Bordeaux, Gironde, 33075, France|CHU de Grenoble, Grenoble, Isère, 38043, France|Hôpital Robert Debré, Reims, Marne, 51092, France|CHRU de Lille - Hôpital Huriet, Lille, Nord, 59037, France|Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes, Lyon, Rhone, 69373, France|Hôpital de La Croix Rousse, Lyon, Rhône, 69004, France|Centre Hospitalier Le Mans, Le Mans, Sarthe, 72037, France|Institut Gustave Roussy, Villejuif, Val-de-marne, 94805, France|CHU de Bordeaux - Hopital Saint Andre, Bordeaux, 33000, France|Hopital Saint Andre Unite de Cancerologie Service de Dermatologie, Bordeaux, 33075, France|Centre Hospitalier Universitaire Ambroise Paré, Boulogne-Billancourt, 92104, France|Clinique de la Louvière, Lille, 59042, France|Hôpital D'Instruction des Armées Desgenettes, Lyon, 69003, France|Groupe Hospitalier Archet I Et II, Nice, 06202, France|Hopital Lariboisiere, Paris, 75010, France|Institut Mutualiste Montsouris, Paris, 75014, France|Ophtalmologist office, Paris, 75015, France|Hôpital Saint louis, Paris, 75475, France|Hospices Civils de Lyon - Hopital Lyon Sud, Pierre Benite, 69495, France|Service de PneumologieCHU Lyon Sud, Pierre-bénite, 69495, France|CHU de Reims - Hôpital Robert Debré, Reims, 51092, France|CHU de Reims - Hôpital Robert Debré, Reims, 51100, France|Nouvel Hopital Civil, Strasbourg, 67091, France|Cardiologist Private Practice, Templemars, 59175, France|Institut Gustave Roussy, Villejuif, 94805, France|Universitaetsklinikum Freiburg, Freiburg im Breisgau, Baden-württemberg, 79104, Germany|University Clinic Heidelberg - PPDS, Heidelberg, Baden-württemberg, 69120, Germany|Klinikum Mannheim Universitätsklinikum gGmbH, Mannheim, Baden-württemberg, 68135, Germany|Universitätsklinikum Tübingen, Tübingen, Baden-württemberg, 72076, Germany|Universitätsklinikum Ulm, Ulm, Baden-württemberg, 89070, Germany|Hautklinik, Klinikum Nürnberg, Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Nuernberg, Bavaria, 90419, Germany|Klinikum Bayreuth GmbH, Bayreuth, Bayern, 95445, Germany|LMU Klinikum der Universität München, München, Bayern, 80337, Germany|LMU Klinikum, München, Bayern, 80337, Germany|Institut für Röntgendiagnostik, Regensburg, Bayern, 93053, Germany|University Clinic Regensburg - PPDS, Regensburg, Bayern, 93053, Germany|Universitätsklinikum Würzburg, Würzburg, Bayern, 97080, Germany|Universitätsklinikum Frankfurt, Frankfurt, Hessen, 60590, Germany|Gesundheit Nordhessen Holding AG, Kassel, Hessen, 34125, Germany|Klinikum Kassel, Kassel, Hessen, 34125, Germany|Zentrum für Radiologie, Kassel, Hessen, 34125, Germany|Augenarztzentrum Buxtehude, Buxtehude, Niedersachsen, 21614, Germany|Elben Klinken Stade ? Buxtehude, Buxtehude, Niedersachsen, 21614, Germany|Augenklinik Universitätsklinikum Bonn, Bonn, Nordrhein-westfalen, 53127, Germany|Institut für Diagnostische Radiologie, Neuroradiologie und Nuklearmedizin, Minden, Nordrhein-westfalen, 32429, Germany|Johannes Wesling Klinikum Minden, Minden, Nordrhein-westfalen, 32429, Germany|Mühlenkreiskliniken - Johannes Wesling Klinikum Minden, Minden, Nordrhein-westfalen, 32429, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Rheinland-pfalz, 55131, Germany|Universitätsklinik Magdeburg, Magdeburg, Sachsen-anhalt, 39120, Germany|Universitätsklinikum Magdeburg A.ö.R., Magdeburg, Sachsen-anhalt, 39120, Germany|Klinik und Poliklinik für Augenheilkunde, Dresden, Sachsen, 01307, Germany|Universitatsklinikum Leipzig AoR, Leipzig, Sachsen, 04103, Germany|Universitatsklinikum Leipzig, Leipzig, Sachsen, 04103, Germany|University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Schleswig-holstein, 24105, Germany|Universitatsklinikum Schleswig-Holstein, Luebeck, Schleswig-holstein, 23562, Germany|Universitatsklinikum Schleswig-Holstein - Kiel, Lübeck, Schleswig-holstein, 23538, Germany|Universitatsklinikum Schleswig-Holstein, Campus Lubeck, Lübeck, Schleswig-holstein, 23538, Germany|Charite-Universitaetsmedizin Berlin, Berlin, 10117, Germany|Universitätsklinikum Bonn, Bonn, 53105, Germany|Universitätsklinikum Bonn, Bonn, 53127, Germany|University Hospital Carl Gustav Carus at the Technical University of Dresden, Dresden, 01307, Germany|Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden, 01307, Germany|Überörtliche Radiologische Gemeinschaftspraxis Dresden, Dresden, 01309, Germany|Diagnostische und interventionelle Radiologie und Neuroradiologie, Erfurt, 99089, Germany|Klinik fur Hautkrankheiten und Allergologie, Helios Hauttumorzentrum Erfurt, Helios Klinikum Erfurt, Erfurt, 99089, Germany|Universitätsklinikum Essen, Essen, 45147, Germany|Goethe-University Frankfurt/Main, Frankfurt/Main, 60590, Germany|Universitätsklinikum Freiburg, Klinik für Radiologie, Freiburg, 79106, Germany|Institut für Diagnostische und Interventionelle Radiologie, Gera, 07548, Germany|SRH Wald-Klinikum Gera GmbH, Gera, 07548, Germany|Klinik für Augenheilkunde, Gera, 75478, Germany|Universitätsklinik Hamburg Eppendorf, Hamburg, 20246, Germany|Augenärzte am Kröpcke, Hannover, 30159, Germany|Medizinische Hochschule Hannover (Hannover Medical School), Hannover, 30625, Germany|Institut für Diagnostische und Interventionelle Radilogie, Hannover, 30626, Germany|University Clinic Heidelberg - PPDS, Heidelberg, 69120, Germany|Universität des Saarlandes, Homburg, 66421, Germany|Universitatsklinikum Schleswig-Holstein - Kiel, Kiel, 24105, Germany|Universitatsklinikum Schleswig-Holstein, Kiel, 24105, Germany|University Hospital Schleswig-Holstein, Campus Kiel, Kiel, 24105, Germany|Universitatsklinikum Schleswig-Holstein, Lübeck, 23538, Germany|Universitätsaugenklinik, Magdeburg, 39120, Germany|Universitätsklinik für Radiologie und Nuklearmedizin, Magdeburg, 39120, Germany|University Hospital Mainz, Mainz, 55131, Germany|Augenklinik Universitätsklinikum Mannheim, Mannheim, 68167, Germany|Augen-Praxis_Minden, Minden, 32427, Germany|LMU Klinikum der Universität, München, 80336, Germany|Hautklinik, Klinikum Nürnberg, Universitätsklinik der Paracelsus Medizinischen Privatuniversität, München, 81677, Germany|Fachklinik Hornheide Abteilung für Internistische Onkologie und Hämatologie, Münster, 48157, Germany|Klinikum Nürnberg - Campus Nord, Nürnberg, 90419, Germany|Klinik & Poliklinik für Augenheilkunde, Regensburg, 93053, Germany|Universitätsklinikum Tübingen, Tübingen, 72076, Germany|Internistische Schwerpunktpraxis Kardiologie Hämatologie Onkologie, Ulm, 89073, Germany|Universitätsklinikum Ulm, Ulm, 89081, Germany|Hygeia Diagnostic and Therapeutic Centre of Athens, Athens, Attiki, 15123, Greece|Laiko General Hospital of Athens, Athens, 115 27, Greece|Laiko General Hospital of Athens, Athens, 11527, Greece|Metropolitan Hospital, Athens, 185 47, Greece|Metropolitan Hospital, Neo Faliro, 185 47, Greece|Metropolitan Hospital, Piraeus, 185 47, Greece|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hajdú-bihar, 4032, Hungary|Magyar Honvédség Egészségügyi Központ, Budapest, 01062, Hungary|Eszak-Pesti Centrumkorhaz -Honvedkorhaz- Podmaniczky utcai telephely, Budapest, 1062, Hungary|Orszagos Onkologiai Intezet, Budapest, H-1122, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, 4032, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok, 05004, Hungary|Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok, 5004, Hungary|Rambam Health Care Campus, Haifa, Hatsafon, 3109601, Israel|Rambam Health Care Campus, Haifa, Heifa, 31096, Israel|Sheba Medical Center - PPDS, Ramat Gan, Tel-aviv, 5262100, Israel|Rambam Health Care Campus, Haifa, 3109600, Israel|Rambam Health Care Campus, Haifa, 3109601, Israel|Hadassah Medical Center - PPDS, Jerusalem, 91120, Israel|Rambam Health Care Campus, Haifa, Ḥeifā, 3109601, Israel|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona-Umberto I G.M. Lancisi G. Salesi, Torrette Site, Ancona, 60126, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Campania, 80131, Italy|Azienda Ospedaliero Universitaria Di Bologna Policlinico S Orsola Malpighi-Via Massarenti, Bologna, Emilia-romagna, 40138, Italy|Azienda Ospedaliero Universitaria Di Bologna Policlinico S Orsola Malpighi, Bologna, Emilia-romagna, 40138, Italy|Policlinico Universitario Campus Biomedico Di Roma, Roma, Lazio, 00128, Italy|Istituto Nazionale Tumori Regina Elena, Roma, Lazio, 00144, Italy|Istituto Dermopatico dell'Immacolata IRCCS, Roma, Lazio, 00167, Italy|Azienda Ospedaliera Sant'Andrea, Roma, Lazio, 00189, Italy|Policlinico Universitario Campus Biomedico Di Roma, Roma, Lazio, 128, Italy|ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia - INCIPIT - PIN, Brescia, Lombardia, 25123, Italy|Azienda Ospedaliera Ospedale Di Lecco, Lecco, Lombardia, 23900, Italy|Istituto Nazionale Dei Tumori, Milano, Lombardia, 20133, Italy|ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda, Milano, Lombardia, 20162, Italy|Istituto Europeo Di Oncologia, Milan, Lombardia, 20141, Italy|ASST di Monza - Azienda Ospedaliera San Gerardo, Monza, Lombardia, 20900, Italy|Azienda Ospedaliera San Gerardo, Monza, Lombardia, 20900, Italy|Istituto Clinico Humanitas - Humanitas Cancer Center, Rozzano, Lombardia, 20089, Italy|Istituto Clinico Humanitas, Rozzano, Lombardia, 20089, Italy|Fondazione del Piemonte per l'Oncologia (IRCCS), Candiolo, Torino, 10060, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Toscana, 56126, Italy|Azienda Ospedaliera S Maria Di Terni, Terni, Umbria, 05100, Italy|Azienda Ospedaliera Santa Maria di Terni, Terni, Umbria, 05100, Italy|Clinica Oculistica, Padua, Veneto, 35128, Italy|IRCCS Giovanni Paolo II Cancer Institute, Bari, 70126, Italy|ASST Papa Giovanni XXIII - Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, 24127, Italy|Azienda Ospedaliero Universitaria Di Bologna - Policlinico S.Orsola Malpighi, Bologna, 40138, Italy|IRCCS Az. Osp. Universitaria San Martino- IST, Genoa, 16132, Italy|Istituto Europeo Di Oncologia, Milano, 20141, Italy|Istituto Nazionale per lo studio e la cura dei tumori Fondazione Giovanni Pascale, Napoli, 80131, Italy|Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale, Napoli, 80131, Italy|Istituto Oncologico Veneto - I.R.C.C.S., Padova, 16132, Italy|Fondazione IRCCS Policlinico San Matteo di Pavia, Pavia, 27100, Italy|Azienda Ospedaliera Civile Maria Paternò Arezzo Ragusa, Ragusa, 97100, Italy|S. C. Oncologia Medica Presidio Ospedaliero Maria Paterno Arezzo, Ragusa, 97100, Italy|Policlinico Universitario Campus Biomedico, Rome, 00128, Italy|Azienza Ospedaliera Universitaria Senese, Siena, 53100, Italy|Ospedale Koelliker, Torino, 10134, Italy|Azienda Sanitaria Universitaria Integrata di Udine - PO Universitario Santa Maria della Misericordia, Udine, 33100, Italy|Kyushu University Hospital, Fukuoka-shi, Fukuoka, 812-8582, Japan|Shinshu University Hospital, Matsumoto, Nagano, 390-8621, Japan|Niigata Cancer Center Hospital, Niigata-Shi, Niigata, 951-8133, Japan|Niigata Cancer Center Hospital, Niigata-shi, Niigata, 951-8566, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, 104-0045, Japan|Niigata Cancer Center Hospital, Niigata, 951-8566, Japan|National Hospital Organization Osaka National Hospital, Osaka, Ôsaka, 540-0006, Japan|Samsung Medical Center - PPDS, Gangnam-Gu, Seoul Teugbyeolsi, 06351, Korea, Republic of|Asan Medical Center - PPDS, Seoul, Seoul Teugbyeolsi, 05505, Korea, Republic of|Asan Medical Center - PPDS, Songpa-Gu, Seoul Teugbyeolsi, 05505, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [seoul], 03080, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital Yonsei University Health System - PPDS, Seoul, 03722, Korea, Republic of|Asan Medical Center - PPDS, Seoul, 05505, Korea, Republic of|Samsung Medical Center - PPDS, Seoul, 06351, Korea, Republic of|Seoul National University Hospital, Seoul, 110-744, Korea, Republic of|Severance Hospital Yonsei University Health System - PPDS, Seoul, 120-752, Korea, Republic of|Samsung Medical Center - PPDS, Seoul, 135-710, Korea, Republic of|Instituto Nacional de Cancerologia, Mexico, DF, 14080, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, 64460, Mexico|Cancun Oncology Center Galenia, Cancun, Quintana ROO, 77505, Mexico|Medica Sur, S. A. B de C. V. (Centro de Investigación Farmacológica y Biotecnológica CIF-BIOTEC), Mexico, 14050, Mexico|Instituto Nacional de Cardiología Ignacio Chavez, Mexico, 14080, Mexico|Medisch Centrum Leeuwarden, Leeuwarden, Friesland, 8934 AD, Netherlands|Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, 6525 GA, Netherlands|Zuyderland Medisch Centrum, Heerlen, Limburg, 6419 PC, Netherlands|VU Medisch Centrum, Amsterdam, Noord Holland, 1081 HV, Netherlands|Amphia Ziekenhuis, Breda, Noord-brabant, 4818 CK, Netherlands|Amphia Ziekenhuis, Breda, Noord-brabant, 4818CK, Netherlands|Maxima Medisch Centrum, Eindhoven, Noord-brabant, 5631 BM, Netherlands|Maxima Medisch Centrum, Veldhoven, Noord-brabant, 5504 DB, Netherlands|Medisch Spectrum Twente, Enschede, Overijssel, 7513 ER, Netherlands|Isala Zwolle, Zwolle, Overijssel, 8025 AB, Netherlands|Medisch Spectrum Twente - Hospital, Ariënsplein Enschede, 7513 JX, Netherlands|Medisch Spectrum Twente, Enschede, 7512 KZ, Netherlands|Universitair Medisch Centrum Groningen, Groningen, 9713 GZ, Netherlands|Zuyderland Medisch Centrum - Heerlen, Heerlen, 6419 PC, Netherlands|Leids Universitair Medisch Centrum, Leiden, 2300 RC, Netherlands|Maastricht University Medical Center, Maastricht, 6229 HX, Netherlands|Erasmus MC, Rotterdam, 3015 CE, Netherlands|Erasmus MC-Daniel den Hoed Oncologisch Centrum, Rotterdam, 3075 EA, Netherlands|Zuyerland Medisch Centrum, Sittard-Geleen, 6162 BG, Netherlands|Oslo universitetssykehus HF, Utprøvingsenheten, Oslo, 379, Norway|Oslo universitetssykehus HF, Oslo, 379, Norway|Oslo Myeloma Center - PPDS, Oslo, NO-0424, Norway|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie, Warsaw, Mazowieckie, 02-781, Poland|Centrum Medyczne MAVIT Sp. z o.o., Warszawa, Mazowieckie, 01-673, Poland|Lux Med, Warszawa, 00-001, Poland|Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon, Lisboa, 1099-023, Portugal|Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS, Porto, Proto, 4200-072, Portugal|Hospital Garcia de Orta*E.P.E., Almada, Setúbal, 2801-951, Portugal|Hospital Garcia de Orta*E.P.E., Almada, 2801-951, Portugal|Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS, Lisboa, 1099-023, Portugal|Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisboa, 1099-023, Portugal|Centro Hospitalar de Lisboa Norte, E.P.E- Hospital de Santa Maria, Lisboa, 1649-035, Portugal|Centro Hospitalar Universitario Lisboa Norte E.P.E, Lisboa, 1649-035, Portugal|Hospital de Santa Maria-Avenida Prof. Egas Moniz - PPDS, Lisboa, 1649-035, Portugal|Hospital de Santa Maria, Lisboa, 1649-035, Portugal|Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS, Porto, 4200-072, Portugal|Russian Oncology Research Center n a N N Blokhin, Moscow, 115478, Russian Federation|Ryazan Regional Clinical Oncology Dispensary, Ryazan', 390027, Russian Federation|Ryazan Clinical Hospital n.a. Semashko, Ryazan, 390005, Russian Federation|Ryazan Regional Clinical Oncology Dispensary, Ryazan, 390011, Russian Federation|Scientific Research Institute of Oncology n.a. N.N. Petrov, St. Petersburg, 197758, Russian Federation|National Cancer Centre - 30 Hospital Blvd, Singapore, 168583, Singapore|Singapore General Hospital (SGH), Singapore, 169608, Singapore|National Cancer Centre - 30 Hospital Blvd, Singapore, 169610, Singapore|National Cancer Centre Singapore, Singapore, 169610, Singapore|Singapore National Eye Research Centre, Singapore, 169610, Singapore|Nemocnica Svateho Michala, a.s., Bratislava, 811 08, Slovakia|Narodny onkologicky ustav - PPDS, Bratislava, 833 01, Slovakia|Narodny onkologicky ustav - PPDS, Bratislava, 833 10, Slovakia|BIONT, a.s., Bratislava, 842 29, Slovakia|POKO POPRAD, s.r.o., Poprad, 058 01, Slovakia|Steve Biko Academic Hospital, Pretoria, 00002, South Africa|Mary Potter Oncology Centre, Pretoria, 27, South Africa|Hospital Universitario de Jerez, Jerez De La Frontera, Andalucía, 11407, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, 33011, Spain|Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, 08916, Spain|Cetir, Centre Mèdic, S.L, Barcelona, Cataluña, 08029, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, 28220, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, Madrid, 28222, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, 28850, Spain|Hospital Clinico Universitario Virgen de la Arrixaca, El Palmar, Murcia, 30120, Spain|Clinica Universidad Navarra, Pamplona, Navarra, 31005, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, 31008, Spain|Clinica Universidad Navarra, Pamplona, Navarra, 31008, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, 31008, Spain|Hospital Universitario de Navarra, Pamplona, Navarra, 31008, Spain|Hospital Nuestra Señora de Valme, Seville, Sevilla, 41014, Spain|Hospital General Universitario de Alicante, Alicante, 03010, Spain|Hospital General Universitario Dr. Balmis, Alicante, 3010, Spain|Hospital Universitario Germans Trias i Pujol, Badalona, 08916, Spain|Centro de Oftalmologia Barraquer, Barcelona, 08021, Spain|Hospital Universitario Vall d'Hebron - PPDS, Barcelona, 08035, Spain|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|Hospital Clinic provincial de Barcelona, Barcelona, 08036, Spain|Hospital de La Santa Creu i Sant Pau, Barcelona, 08041, Spain|Hospital Clinic de Barcelona, Barcelona, 8036, Spain|Hospital de La Santa Creu i Sant Pau, Barcelona, 8041, Spain|Onkologikoa, Donostia-san Sebastián, 20014, Spain|Hospital Universitario Virgen de las Nieves, Granada, 18014, Spain|Hospital Universitario A Coruña, La Coruna, 15006, Spain|Hospital Arnau de Vilanova, Lleida, 25198, Spain|Hospital Universitari Arnau de Vilanova, Lleida, 25198, Spain|Hospital General Universitario Gregorio Maranon, Madrid, 28007, Spain|Hospital General Universitario Gregorio Maranon, Madrid, 28009, Spain|Hospital Universitario 12 de Octubre, Madrid, 28026, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario La Paz - PPDS, Madrid, 28046, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, 28222, Spain|Hospital Civil (Hospital Regional Universitario de Malaga), Malaga, 29011, Spain|Hospital Regional Universitario de Malaga ? Hospital General, Malaga, 29011, Spain|Hospital Universitario Virgen del Rocio - PPDS, Sevilla, 41013, Spain|Fundacion Instituto Valenciano de Oncologia, Valencia, 46009, Spain|Gävle Sjukhus, Gavle, SE-801 87, Sweden|Sahlgrenska Universitetssjukhuset, Göteborg, SE-41345, Sweden|Universitetssjukhuset i Linköping, Linköping, 581 85, Sweden|Skanes Universitetssjukhus Lund, Lund, 22221, Sweden|Karolinska Universitetssjukhuset Solna, Solna, 171 64, Sweden|Uppsala Universitet, Uppsala, 751 85, Sweden|Universitätsspital Zürich, Zurich, Zürich (DE), 8091, Switzerland|Inselspital Bern, Bern, 3010, Switzerland|Universitätsspital Zürich, Zurich Flughafen, 8058, Switzerland|Dr. med. Nicole Gasser, Zürich, 8044, Switzerland|Dr.med. Ursula Urner, Zürich, 8044, Switzerland|Institut für diagnostische und interventionelle Radiologie, Zürich, 8091, Switzerland|Gazi University Medical Faculty Gazi Hospital, Ankara, 6500, Turkey|Ege University Medical Faculty, Bornova, 35100, Turkey|Ege University Medical aculty, Izmir, 35100, Turkey|Sifa Universitesi Bornova Egitim Arastirma Hastanesi, Izmir, 35100, Turkey|Addenbrookes Hospital, Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom|Mid Essex Hospital Services NHS Trust, Broomfield, Chelmsford, Essex, CM1 7ET, United Kingdom|The Royal Marsden NHS Foundation Trust, London, Chelsea, SW3 6JJ, United Kingdom|Royal Preston Hospital, Preston, Lancashire, PR2 9HT, United Kingdom|Royal Marsden Hospital - Surrey, London, London, CITY OF, SW3 6JJ, United Kingdom|The Royal Marsden in Sutton, Surrey - Downs Rd, London, London, CITY OF, SW3 6JJ, United Kingdom|Mount Vernon Hospital, Northwood, London, CITY OF, HA6 2RN, United Kingdom|Royal Surrey County Hospital, Guildford, Surrey, GU2 7XX, United Kingdom|Clatterbridge Hospital - NWCRN - PPDS, Bebbington, Wirral, CH63 4JY, United Kingdom|Clatterbridge Hospital - PPDS, Bebington, Wirral, CH63 4JY, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, CH63 4JY, United Kingdom|Weston Park Hospital, Sheffield, York, S10 2SJ, United Kingdom|Broomfield Hospital, Broomfield, CM1 7ET, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, United Kingdom|St James University Hospital, Leeds, LS9 7TF, United Kingdom|Royal Free Hospital, London, NW32QG, United Kingdom|The Christie NHS Foundation Trust - PPDS, Manchester, M20 4BX, United Kingdom|Churchill Hospital, Oxford, OX2 7JL, United Kingdom|Churchill Hospital, Oxford, OX3 7LE, United Kingdom|Royal Preston Hospital - NWCRN- PPDS, Preston, PR2 9HT, United Kingdom|Royal Preston Hospital - PPDS, Preston, PR2 9HT, United Kingdom|Clatterbridge Cancer Centre, Wirral, CH63 3JY, United Kingdom",
